Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06570850

Colistin Monotherapy vs Colsitin-fosfomycine in CRAB Infection

Efficacy of Colistin Monotherapy Versus Colistin Combined With Fosfomycin Against Carbapenem-Resistant Acinetobacter Baumannii Infections

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
188 (estimated)
Sponsor
Chiang Mai University · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

The goal of this clinical trial is to evaluate the efficacy of colistin compared with colistin plus fosfomycin against carbapenem-resistant Acinetobacter baumanii infection in Thailand. The main questions it aims to answer the following main questions: 1. Which group has better clinical response at end of treatment 2. Which group has better clinical response at 72 hours and micrological cure at 72 hours and at end of treatment

Detailed description

Participants will be randomized in a 1:1 ratio to receive a combination of intravenous colistin plus intravenous fosfomycin (combination group) or colistin alone (monotherapy group) to determine if monotherapy or combination therapy has a better outcome.

Conditions

Interventions

TypeNameDescription
DRUGColistin Sodium MethanesulfonateIntravenous colistin (colistinmethate soidum) 5 mg/kg/day intravenous (dosage will be adjusted according to creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.
DRUGColistin Sodium Methanesulfonate plus FosfomycinIntravenous colistin(dosage is same as colistin group) plus intravenous fosfomycin(dosage will be adjusted according to MIC and creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.

Timeline

Start date
2023-04-01
Primary completion
2025-03-01
Completion
2025-07-01
First posted
2024-08-26
Last updated
2024-08-26

Locations

1 site across 1 country: Thailand

Source: ClinicalTrials.gov record NCT06570850. Inclusion in this directory is not an endorsement.